Pharma Stocks: Cipla, Lupin, Sun Pharma — Where is upside and who faces downside in GLP-1 boom?
Brokerges remains selective on the pharma space, with a largely cautious stance. Out of its coverage, the brokerage has a Buy rating on only one stock. Two stocks are rated Neutral. Meanwhile, three stocks carry Sell ratings, indicating a higher downside risk in most of their coverage universe.
Brokerges remains selective on the pharma space, with a largely cautious stance. Out of its coverage, the brokerage has a Buy rating on only one stock. Two stocks are rated Neutral. Meanwhile, three stocks carry Sell ratings, indicating a higher downside risk in most of their coverage universe.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
